Mga Batayang Estadistika
| LEI | 549300YVHWP0YJ1YW816 |
| CIK | 1325618 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to IRADIMED CORPORATION
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| September 3, 2025 |
IRADIMED CORPORATION INSIDER TRADING POLICY Exhibit 19.1 IRADIMED CORPORATION INSIDER TRADING POLICY This Insider Trading Policy (this “Policy”) supersedes all previous insider trading policies adopted by our Board (as defined below). After you have read this policy, please sign the Certification that is attached to this Policy and return it to the Compliance Officer (as defined below) at the address indicated on the Certification. INTRODUC |
|
| September 3, 2025 |
NOTICE OF GRANT OF RESTRICTED STOCK UNIT AWARD IRADIMED CORPORATION 2023 EQUITY INCENTIVE PLAN Exhibit 10.12 NOTICE OF GRANT OF RESTRICTED STOCK UNIT AWARD (PERFORMANCE-VESTING) IRADIMED CORPORATION 2023 EQUITY INCENTIVE PLAN FOR GOOD AND VALUABLE CONSIDERATION, Iradimed Corporation (the “Company”) hereby grants this Restricted Stock Unit Award (the “Award”) of the number of Restricted Stock Units set forth in this Notice of Grant of Restricted Stock Unit Award (the “Notice”) to the Grantee |
|
| September 3, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K/A (Amendment No. 1) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NO. 0 |
|
| September 3, 2025 |
NOTICE OF GRANT OF RESTRICTED STOCK UNIT AWARD IRADIMED CORPORATION 2023 EQUITY INCENTIVE PLAN Exhibit 10.8 NOTICE OF GRANT OF RESTRICTED STOCK UNIT AWARD IRADIMED CORPORATION 2023 EQUITY INCENTIVE PLAN FOR GOOD AND VALUABLE CONSIDERATION, Iradimed Corporation (the “Company”) hereby grants this Restricted Stock Unit Award (the “Award”) of the number of Restricted Stock Units set forth in this Notice of Grant of Restricted Stock Unit Award (the “Notice”) to the Grantee designated in this Not |
|
| September 3, 2025 |
NOTICE OF GRANT OF RESTRICTED STOCK UNIT AWARD IRADIMED CORPORATION 2023 EQUITY INCENTIVE PLAN Exhibit 10.11 NOTICE OF GRANT OF RESTRICTED STOCK UNIT AWARD IRADIMED CORPORATION 2023 EQUITY INCENTIVE PLAN FOR GOOD AND VALUABLE CONSIDERATION, Iradimed Corporation (the “Company”) hereby grants this Restricted Stock Unit Award (the “Award”) of the number of Restricted Stock Units set forth in this Notice of Grant of Restricted Stock Unit Award (the “Notice”) to the Grantee designated in this No |
|
| September 3, 2025 |
NOTICE OF GRANT OF RESTRICTED STOCK UNIT AWARD IRADIMED CORPORATION 2023 EQUITY INCENTIVE PLAN Exhibit 10.9 NOTICE OF GRANT OF RESTRICTED STOCK UNIT AWARD IRADIMED CORPORATION 2023 EQUITY INCENTIVE PLAN FOR GOOD AND VALUABLE CONSIDERATION, Iradimed Corporation (the “Company”) hereby grants this Restricted Stock Unit Award (the “Award”) of the number of Restricted Stock Units set forth in this Notice of Grant of Restricted Stock Unit Award (the “Notice”) to the Grantee designated in this Not |
|
| September 3, 2025 |
NOTICE OF GRANT OF RESTRICTED STOCK UNIT AWARD IRADIMED CORPORATION 2023 EQUITY INCENTIVE PLAN Exhibit 10.10 NOTICE OF GRANT OF RESTRICTED STOCK UNIT AWARD IRADIMED CORPORATION 2023 EQUITY INCENTIVE PLAN FOR GOOD AND VALUABLE CONSIDERATION, Iradimed Corporation (the “Company”) hereby grants this Restricted Stock Unit Award (the “Award”) of the number of Restricted Stock Units set forth in this Notice of Grant of Restricted Stock Unit Award (the “Notice”) to the Grantee designated in this No |
|
| September 2, 2025 |
Exhibit 99.1 IRADIMED CORPORATION ANNOUNCES BOARD TRANSITION: ANTHONY VUOTO RETIRES, JOE KIANI APPOINTED AS NEW DIRECTOR Orlando, Florida, September 2, 2025 – IRADIMED CORPORATION (“Iradimed” or the “Company”) (NASDAQ: IRMD), a leader in innovative medical devices for Magnetic Resonance Imaging (“MRI”)-compatible patient monitoring and infusion systems, today announced a Board of Directors (the “B |
|
| September 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): August 27, 2025 IRADIMED CORPORATION (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-36534 73-1408526 (Commission Fi |
|
| August 1, 2025 |
Exhibit 99.1 IRADIMED CORPORATION Reports Record Second Quarter 2025 Financial Results Announces Regular Quarterly Cash Dividend of $0.17 Per Share Raises Full Year 2025 Revenue and Earnings Guidance ● Reports record revenue of $20.4 million for the second quarter of 2025, an increase of $2.5 million, or 14%, compared to the same period in 2024. ● Reports record GAAP diluted EPS of $0.45 and non-G |
|
| August 1, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No.: 001-36534 IRADIM |
|
| August 1, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE Date of report (Date of earliest event reported): August 1, 2025 IRADIMED CORPORATION (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-36534 73-1408526 (Commission File Number) (IRS Employer Identification No. |
|
| June 23, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): June 23, 2025 IRADIMED CORPORATION (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-36534 73-1408526 (Commission File |
|
| May 29, 2025 |
IRADIMED CORPORATION Announces FDA 510(k) Clearance for MRidium® 3870 Infusion Pump System IRADIMED CORPORATION Announces FDA 510(k) Clearance for MRidium® 3870 Infusion Pump System Winter Springs, Florida, May 29, 2025 – Iradimed Corporation (NASDAQ: IRMD), a global leader in innovative medical devices for MRI environments, today announced that the U. |
|
| May 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): May 29, 2025 IRADIMED CORPORATION (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-36534 73-1408526 (Commission File |
|
| May 5, 2025 |
Exhibit 99.1 IRADIMED CORPORATION Announces First Quarter 2025 Financial Results Announces Regular Quarterly Cash Dividend of $0.17 Per Share Reaffirms Full Year 2025 Revenue and Earnings Guidance ● Reports record revenue of $19.5 million for the first quarter of 2025, an increase of $1.9 million or 11%, compared to the same period in 2024. ● Reports GAAP diluted EPS of $0.37 and non-GAAP diluted |
|
| May 5, 2025 |
Employment Agreement between Iradimed Corporation and Jeffrey Chiprin, dated November 26, 2024. Exhibit 10.1 EMPLOYMENT AGREEMENT This Employment Agreement (the “Agreement”) is made on the 26th day of November 2024 between Iradimed Corporation, a Delaware corporation, having offices at 1025 Willa Springs Drive, Winter Springs, Florida (“Iradimed” or Company’’), and Jeff Chiprin (“Executive”). WITNESSETH: WHEREAS, Iradimed desires to employ Executive upon the terms and conditions hereinafter |
|
| May 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No.: 001-36534 IRADI |
|
| May 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE Date of report (Date of earliest event reported): May 5, 2025 IRADIMED CORPORATION (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-36534 73-1408526 (Commission File Number) (IRS Employer Identification No. |
|
| April 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| March 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NO. 001-36534 IRADIMED CO |
|
| March 6, 2025 |
Exhibit 10.12 NOTICE OF GRANT OF RESTRICTED STOCK UNIT AWARD (PERFORMANCE-VESTING) IRADIMED CORPORATION 2023 EQUITY INCENTIVE PLAN FOR GOOD AND VALUABLE CONSIDERATION, Iradimed Corporation (the “Company”) hereby grants this Restricted Stock Unit Award (the “Award”) of the number of Restricted Stock Units set forth in this Notice of Grant of Restricted Stock Unit Award (the “Notice”) to the Grantee |
|
| March 6, 2025 |
Exhibit 10.8 NOTICE OF GRANT OF RESTRICTED STOCK UNIT AWARD IRADIMED CORPORATION 2023 EQUITY INCENTIVE PLAN FOR GOOD AND VALUABLE CONSIDERATION, Iradimed Corporation (the “Company”) hereby grants this Restricted Stock Unit Award (the “Award”) of the number of Restricted Stock Units set forth in this Notice of Grant of Restricted Stock Unit Award (the “Notice”) to the Grantee designated in this Not |
|
| March 6, 2025 |
Exhibit 19.1 IRADIMED CORPORATION INSIDER TRADING POLICY This Insider Trading Policy (this “Policy”) supersedes all previous insider trading policies adopted by our Board (as defined below). After you have read this policy, please sign the Certification that is attached to this Policy and return it to the Compliance Officer (as defined below) at the address indicated on the Certification. INTRODUC |
|
| March 6, 2025 |
Exhibit 10.11 NOTICE OF GRANT OF RESTRICTED STOCK UNIT AWARD IRADIMED CORPORATION 2023 EQUITY INCENTIVE PLAN FOR GOOD AND VALUABLE CONSIDERATION, Iradimed Corporation (the “Company”) hereby grants this Restricted Stock Unit Award (the “Award”) of the number of Restricted Stock Units set forth in this Notice of Grant of Restricted Stock Unit Award (the “Notice”) to the Grantee designated in this No |
|
| March 6, 2025 |
Exhibit 10.10 NOTICE OF GRANT OF RESTRICTED STOCK UNIT AWARD IRADIMED CORPORATION 2023 EQUITY INCENTIVE PLAN FOR GOOD AND VALUABLE CONSIDERATION, Iradimed Corporation (the “Company”) hereby grants this Restricted Stock Unit Award (the “Award”) of the number of Restricted Stock Units set forth in this Notice of Grant of Restricted Stock Unit Award (the “Notice”) to the Grantee designated in this No |
|
| March 6, 2025 |
Exhibit 10.9 NOTICE OF GRANT OF RESTRICTED STOCK UNIT AWARD IRADIMED CORPORATION 2023 EQUITY INCENTIVE PLAN FOR GOOD AND VALUABLE CONSIDERATION, Iradimed Corporation (the “Company”) hereby grants this Restricted Stock Unit Award (the “Award”) of the number of Restricted Stock Units set forth in this Notice of Grant of Restricted Stock Unit Award (the “Notice”) to the Grantee designated in this Not |
|
| February 13, 2025 |
Exhibit 99.1 IRADIMED CORPORATION Announces Fourth Quarter and Full Year of 2024 Financial Results and Increases its Regular Quarterly Cash Dividend to $0.17 Per Share from $0.15 Per Share ● Reports record revenue of $19.4 million for the fourth quarter of 2024, an increase of $1.9 million or 11%, compared to the same period in 2023. ● Reports GAAP diluted EPS of $0.40 and non-GAAP diluted EPS of |
|
| February 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE Date of report (Date of earliest event reported): February 13, 2025 IRADIMED CORPORATION (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-36534 73-1408526 (Commission File Number) (IRS Employer Identification No. |
|
| January 10, 2025 |
IRADIMED CORPORATION Reports Preliminary Unaudited Record Fourth Quarter and Full-Year 2024 Revenues IRADIMED CORPORATION Reports Preliminary Unaudited Record Fourth Quarter and Full-Year 2024 Revenues ● Reports preliminary fourth quarter 2024 revenue in the range of approximately $19. |
|
| January 10, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): January 10, 2025 IRADIMED CORPORATION (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-36534 73-1408526 (Commission File Number) (IRS Employer Identification No. |
|
| November 14, 2024 |
SC 13G/A 1 ea0221047-13ga3soleusiradi.htm AMENDMENT NO. 3 TO SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* IRADIMED CORPORATION (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 46266A109 (CUSIP Number) September 30, 2024 (Date of Event Which Requ |
|
| October 31, 2024 |
Exhibit 99.1 IRADIMED CORPORATION Announces Third Quarter of 2024 Financial Results and the Declaration of its Regular Quarterly Cash Dividend of $0.15 Per Share ● Reports record revenue of $18.3 million for the third quarter of 2024, an increase of $1.8 million or 11% over the comparable period 2023. ● Reports GAAP diluted EPS of $0.40 and Non-GAAP diluted EPS of $0.43 for the third quarter of 20 |
|
| October 31, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No.: 001-36534 I |
|
| October 31, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE Date of report (Date of earliest event reported): October 31, 2024 IRADIMED CORPORATION (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-36534 73-1408526 (Commission File Number) (IRS Employer Identification No. |
|
| August 1, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): August 1, 2024 IRADIMED CORPORATION (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-36534 73-1408526 (Commission File Number) (IRS Employer Identification No. |
|
| August 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No.: 001-36534 IRADIM |
|
| August 1, 2024 |
Exhibit 99.1 IRADIMED CORPORATION Announces Second Quarter of 2024 Financial Results and the Declaration of its Regular Quarterly Cash Dividend of $0.15 Per Share ● Reports record revenue of $17.9 million for the second quarter of 2024, an increase of 11.2 percent over the comparable period 2023. ● Reports GAAP diluted EPS of $0.38 and non-GAAP diluted EPS of $0.42 for the second quarter of 2024. |
|
| June 20, 2024 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): June 20, 2024 IRADIMED CORPORATION (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-36534 73-1408526 (Commission File Number) (IRS Employer Identification No. |
|
| June 7, 2024 |
Exhibit 99.1 IRADIMED CORPORATION Announces Uplisting to The Nasdaq Global Market Trading to commence effective on the market open June 14, 2024 Winter Springs, Florida, June 7, 2024 – IRADIMED CORPORATION (“Iradimed”) (NASDAQ: IRMD), a leading provider of innovative magnetic resonance imaging (MRI) compatible medical devices, announced today its common stock will uplist and commence trading on th |
|
| June 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): June 5, 2024 IRADIMED CORPORATION (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-36534 73-1408526 (Commission File |
|
| June 3, 2024 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): May 29, 2024 IRADIMED CORPORATION (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-36534 73-1408526 (Commission File |
|
| June 3, 2024 |
AMENDMENT TO SUSI, LLC LEASE AGREEMENT Exhibit 99.1 AMENDMENT TO SUSI, LLC LEASE AGREEMENT TIDS AMENDMENT TO SUSI, LLC LEASE AGREEMENT (this “Amendment”) is made May 29, 2024 (the “Effective Date”) between SUSI, LLC, a Florida limited liability company (“Landlord”), and IRADIMED CORPORATION, a Delaware corporation (“Tenant”). RECITALS A. Landlord and Tenant are parties to that certain Susi, LLC Lease Agreement dated as of January 17, 2 |
|
| May 6, 2024 |
IRADIMED CORPORATION 1025 Willa Springs Drive Winter Springs, Florida 32708 IRADIMED CORPORATION 1025 Willa Springs Drive Winter Springs, Florida 32708 VIA EDGAR May 6, 2024 United States Securities and Exchange Commission Division of Corporation Finance 100 F Street NE Washington, D. |
|
| May 6, 2024 |
As Filed with the Securities and Exchange Commission on May 6, 2024 As Filed with the Securities and Exchange Commission on May 6, 2024 Registration No. |
|
| May 3, 2024 |
SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| May 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No.: 001-36534 IRADI |
|
| May 2, 2024 |
Exhibit 99.1 IRADIMED CORPORATION Announces First Quarter of 2024 Financial Results and the Declaration of its Regular Quarterly Cash Dividend of $0.15 Per Share ● Reports record revenue of $17.6 million for the first quarter of 2024. ● Reports GAAP diluted EPS of $0.32 and non-GAAP diluted EPS of $0.36 for the first quarter of 2024. ● Reports first quarter of 2024 operating income of $4.7 million |
|
| May 2, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): May 2, 2024 IRADIMED CORPORATION (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-36534 73-1408526 (Commission File Number) (IRS Employer Identification No. |
|
| April 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| April 3, 2024 |
EXHIBIT 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Iradimed Corporation (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit(1) Maximum Aggregate Offering Price(1) Fee Rate Amount of Registration Fee Equity Common Stock, $0. |
|
| April 3, 2024 |
As Filed with the Securities and Exchange Commission on April 3, 2024 As Filed with the Securities and Exchange Commission on April 3, 2024 Registration No. |
|
| March 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NO. 001-36534 IRADIMED CO |
|
| March 1, 2024 |
Exhibit 21.1 List of Subsidiaries of Iradimed Corporation Legal Name Jurisdiction None Not Applicable |
|
| March 1, 2024 |
Form of Restricted Stock Unit Award Agreement for Iradimed Corporation 2023 Equity Incentive Plan Exhibit 10.16 NOTICE OF GRANT OF RESTRICTED STOCK UNIT AWARD IRADIMED CORPORATION 2023 EQUITY INCENTIVE PLAN FOR GOOD AND VALUABLE CONSIDERATION, Iradimed Corporation (the “Company”) hereby grants this Restricted Stock Unit Award (the “Award”) of the number of Restricted Stock Units set forth in this Notice of Grant of Restricted Stock Unit Award (the “Notice”) to the Grantee designated in this No |
|
| March 1, 2024 |
Exhibit 10.17 NOTICE OF GRANT OF RESTRICTED STOCK UNIT AWARD IRADIMED CORPORATION 2023 EQUITY INCENTIVE PLAN FOR GOOD AND VALUABLE CONSIDERATION, Iradimed Corporation (the “Company”) hereby grants this Restricted Stock Unit Award (the “Award”) of the number of Restricted Stock Units set forth in this Notice of Grant of Restricted Stock Unit Award (the “Notice”) to the Grantee designated in this No |
|
| March 1, 2024 |
Exhibit 10.15 IRADIMED CORPORATION 2023 EQUITY INCENTIVE PLAN Iradimed Corporation, a Delaware corporation (the “Company”), sets forth herein the terms of its 2023 Equity Incentive Plan (the “Plan”), as follows: 1. PURPOSE The Plan is intended to enhance the ability of the Company and its Affiliates (as defined herein) to attract and retain highly qualified officers, non-employee members of the Bo |
|
| March 1, 2024 |
Exhibit 10.18 NOTICE OF GRANT OF RESTRICTED STOCK UNIT AWARD (PERFORMANCE-VESTING) IRADIMED CORPORATION 2023 EQUITY INCENTIVE PLAN FOR GOOD AND VALUABLE CONSIDERATION, Iradimed Corporation (the “Company”) hereby grants this Restricted Stock Unit Award (the “Award”) of the number of Restricted Stock Units set forth in this Notice of Grant of Restricted Stock Unit Award (the “Notice”) to the Grantee |
|
| February 13, 2024 |
IRMD / IRadimed Corporation / Susi Roger E. - SCHEDULE 13G/A Passive Investment SC 13G/A 1 sc13g-a.htm SCHEDULE 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Iradimed Corporation (Name of Issuer) Common Stock (Title of Class of Securities) 46266A109 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to design |
|
| February 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): February 8, 2024 IRADIMED CORPORATION (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-36534 73-1408526 (Commission File Number) (IRS Employer Identification No. |
|
| February 8, 2024 |
IRADIMED CORPORATION Announces Fourth Quarter of 2023 and Full Year of 2023 Financial Results Exhibit 99.1 IRADIMED CORPORATION Announces Fourth Quarter of 2023 and Full Year of 2023 Financial Results ● Reports record revenue of $17.5 million for the fourth quarter and $65.6 million for the full year of 2023. ● Reports GAAP diluted EPS of $0.36 and non-GAAP diluted EPS of $0.39 for the fourth quarter of 2023. ● Reports GAAP diluted EPS of $1.35 and non-GAAP diluted EPS of $1.48 for the ful |
|
| February 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* IRADIMED CORPORATION (Name of Issuer) Common Stock (Title of Class of Securities) 46266A109 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sc |
|
| December 13, 2023 |
EXHIBIT 107 EX=FILING FEES Calculation of Filing Fee Tables Form S-8 (Form Type) Iradimed Corporation (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit(2) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, $0. |
|
| December 13, 2023 |
As filed with the Securities and Exchange Commission on December 13, 2023 As filed with the Securities and Exchange Commission on December 13, 2023 Registration No. |
|
| December 12, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 12, 2023 IRADIMED CORPORATION (Exact Name of Registrant as Specified in Its Charter) 001-36534 (Commission File Number) Delaware 73-1408526 (State or Other Jurisdiction of In |
|
| December 12, 2023 |
EXHIBIT 99.1 IRADIMED CORPORATION Announces Establishment of a Quarterly Dividend of $0.15 per share and a Special Cash Dividend of $0.48 per share Winter Springs, Florida, December 12, 2023 – IRADIMED CORPORATION (the "Company") (NASDAQ: IRMD) announced today that its Board of Directors approved a special cash dividend of $0.48 per share and the initiation of a regular quarterly dividend on the C |
|
| November 6, 2023 |
Iradimed Corporation Incentive-Based Compensation Recovery Policy Exhibit 10.1 IRADIMED CORPORATION INCENTIVE-BASED COMPENSATION RECOVERY POLICY 1. Policy Purpose. The purpose of this Iradimed Corporation (the “Company”) Incentive-Based Compensation Recovery Policy (this “Policy”) is to enable the Company to recover Erroneously Awarded Compensation in the event that the Company is required to prepare an Accounting Restatement. This Policy is intended to comply w |
|
| November 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): November 2, 2023 IRADIMED CORPORATION (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-36534 73-1408526 (Commission File Number) (IRS Employer Identification No. |
|
| November 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No.: 001-36534 I |
|
| November 3, 2023 |
IRADIMED CORPORATION Announces Third Quarter 2023 Financial Results Exhibit 99.1 IRADIMED CORPORATION Announces Third Quarter 2023 Financial Results ● Reports record revenue of $16.5 million for the third quarter of 2023. ● GAAP diluted EPS of $0.40 and non-GAAP diluted EPS of $0.43. ● Third quarter operating income of $5.9 million, an increase of 43% compared to the same period in 2022. Winter Springs, Florida, November 3, 2023 – IRADIMED CORPORATION (the “Compan |
|
| November 3, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): November 3, 2023 IRADIMED CORPORATION (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-36534 73-1408526 (Commission File Number) (IRS Employer Identification No. |
|
| August 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No.: 001-36534 IRADIM |
|
| August 3, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): August 3, 2023 IRADIMED CORPORATION (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-36534 73-1408526 (Commission File Number) (IRS Employer Identification No. |
|
| August 3, 2023 |
IRADIMED CORPORATION Announces Second Quarter 2023 Financial Results Exhibit 99.1 IRADIMED CORPORATION Announces Second Quarter 2023 Financial Results ● Reports record revenue of $16.1 million for the second quarter of 2023 ● GAAP diluted EPS of $0.33 and non-GAAP diluted EPS of $0.36 ● Operating income was $5.0 million and increased by 19% ● Announces third quarter and full year 2023 financial guidance Winter Springs, Florida, August 3, 2023 – IRADIMED CORPORATION |
|
| June 15, 2023 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): June 15, 2023 IRADIMED CORPORATION (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-36534 73-1408526 (Commission File Number) (IRS Employer Identification No. |
|
| May 10, 2023 |
IRADIMED CORPORATION Named a 2023 Best Small Company in America by Forbes EXHIBIT 99.1 IRADIMED CORPORATION Named a 2023 Best Small Company in America by Forbes Winter Springs, Florida, May 10, 2023 – IRADIMED CORPORATION (the “Company”) (NASDAQ: IRMD), was recently named on Forbes’ latest list of America’s Best Small Companies for 2023. Iradimed is a leader in the development of innovative magnetic resonance imaging (“MRI”) medical devices and the only known provider o |
|
| May 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 10, 2023 IRADIMED CORPORATION (Exact Name of Registrant as Specified in Its Charter) 001-36534 (Commission File Number) Delaware 73-1408526 (State or Other Jurisdiction of Incorpo |
|
| May 4, 2023 |
IRADIMED CORPORATION Announces First Quarter 2023 Financial Results Exhibit 99.1 IRADIMED CORPORATION Announces First Quarter 2023 Financial Results ● Reports record revenue of $15.5 million for the first-quarter quarter of 2023 ● GAAP diluted EPS of $0.27 and non-GAAP diluted EPS of $0.30 ● Operating income was $4.0 million and increased by 30% ● Announces second quarter 2023 financial guidance and increases full-year 2023 financial guidance Winter Springs, Flori |
|
| May 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): May 4, 2023 IRADIMED CORPORATION (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-36534 73-1408526 (Commission File Number) (IRS Employer Identification No. |
|
| May 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No.: 001-36534 IRADI |
|
| April 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| March 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NO. 001-36534 IRADIMED CO |
|
| February 14, 2023 |
IRMD / Iradimed Corp / Soleus Capital Master Fund, L.P. - SC 13G/A Passive Investment SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* IRADIMED CORPORATION (Name of Issuer) Common Stock (Title of Class of Securities) 46266A109 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to whic |
|
| February 10, 2023 |
IRMD / Iradimed Corp / Nine Ten Capital Management LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 Amendment No.: 3 Name of Issuer: Iradimed Corp Title of Class of Securities: Common CUSIP Number: 46266A109 December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: |
|
| February 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8‑K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): February 6, 2023 IRADIMED CORPORATION (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-36534 73-1408526 (Commission File Number) (IRS Employer Identification No. |
|
| February 3, 2023 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): February 2, 2023 IRADIMED CORPORATION (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-36534 73-1408526 (Commission File Number) (IRS Employer Identification No. |
|
| February 3, 2023 |
EXHIBIT 10.1 REINSTATEMENT AND AMENDMENT TO SALE AND PURCHASE AGREEMENT THIS REINSTATEMENT AND AMENDMENT TO SALE AND PURCHASE AGREEMENT (this “Reinstatement”) is made and entered into this day of January, 2023 (the “Reinstatement Effective Date”) by and between O PROPERTY, LTD., a Florida limited partnership (the “Seller”) and IRADIMED CORPORATION, a Delaware corporation (the “Purchaser”). W I T N |
|
| February 2, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): February 2, 2023 IRADIMED CORPORATION (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-36534 73-1408526 (Commission File Number) (IRS Employer Identification No. |
|
| February 2, 2023 |
EXHIBIT 99.1 IRADIMED CORPORATION Announces Fourth Quarter and Full Year 2022 Financial Results and Announces Special Cash Dividend • Reports fourth quarter 2022 revenue of $14.9 million, GAAP diluted EPS of $0.29 and non-GAAP diluted EPS of $0.32. • Reports full-year 2022 revenue of $53.3 million, GAAP diluted EPS of $1.02 and non-GAAP diluted EPS of $1.10. • The Board of Directors approved a spe |
|
| January 19, 2023 |
IRADIMED CORPORATION Announces Preliminary Financial Results for Fourth Quarter 2022 EXHIBIT 99.1 IRADIMED CORPORATION Announces Preliminary Financial Results for Fourth Quarter 2022 • Reports preliminary fourth quarter 2022 revenue of $14.9 million • Announces full-year and first-quarter 2023 financial guidance Winter Springs, Florida, January 18, 2023 – iRadimed Corporation (the “Company”) (NASDAQ: IRMD) today announced selected preliminary financial results for the fourth quart |
|
| January 19, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): January 18, 2023 IRADIMED CORPORATION (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-36534 73-1408526 (Commission File Number) (IRS Employer Identification No. |
|
| November 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): November 1, 2022 IRADIMED CORPORATION (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-36534 73-1408526 (Commission File Number) (IRS Employer Identification No. |
|
| November 4, 2022 |
EXHIBIT 10.1 SALE AND PURCHASE AGREEMENT THIS SALE AND PURCHASE AGREEMENT (this ?Agreement?) is made and entered into by and between O PROPERTY, LTD., a Florida limited partnership (?Seller?) and IRADIMED CORPORATION, a Delaware corporation (?Purchaser?) as of November 1, 2022 (the ?Effective Date?). RECITALS: A. Seller is the owner of the Real Property located in Orange County, Florida, together |
|
| November 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No.: 001-36534 I |
|
| November 3, 2022 |
EXHIBIT 99.1 IRADIMED CORPORATION Announces Third Quarter 2022 Financial Results ? Revenue was $13.4 million and increased by 23% ? Operating income was $4.1 million and increased by 32% ? GAAP diluted EPS was $0.27 and increased by 35% ? Announces fourth quarter 2022 financial guidance Winter Springs, Florida, November 3, 2022 ? IRADIMED CORPORATION (the "Company") (NASDAQ: IRMD) announced today |
|
| November 3, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): November 3, 2022 IRADIMED CORPORATION (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-36534 73-1408526 (Commission File Number) (IRS Employer Identification No. |
|
| October 11, 2022 |
EXHIBIT 99.1 IRADIMED CORPORATION Withdraws 510(k) with Plans to Resubmit After Further Discussions with FDA Announces Preliminary Financial Results for Third Quarter 2022 Winter Springs, Florida, October 10, 2022 ? iRadimed Corporation (the ?Company?) (NASDAQ: IRMD) today announced that the Company, after learning the FDA would likely not have the time to finish clearance activities for a pending |
|
| October 11, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): October 10, 2022 IRADIMED CORPORATION (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-36534 73-1408526 (Commission File Number) (IRS Employer Identification No. |
|
| October 6, 2022 |
IRADIMED CORPORATION Announces Appointment of Hilda Scharen-Guivel to Board of Directors EXHIBIT 99.1 IRADIMED CORPORATION Announces Appointment of Hilda Scharen-Guivel to Board of Directors Winter Springs, Florida, October 6, 2022 ? iRadimed Corporation (the ?Company?) (NASDAQ: IRMD) today announced the appointment of Hilda Scharen-Guivel to the Iradimed Board of Directors, effective October 4, 2022. Following the appointment of Ms. Scharen-Guivel, the Board will comprise five direct |
|
| October 6, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): October 4, 2022 IRADIMED CORPORATION (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-36534 73-1408526 (Commission File Number) (IRS Employer Identification No. |
|
| September 1, 2022 |
EXHIBIT A JOINT FILING AGREEMENT Soleus Capital Master Fund, L.P., a Cayman Islands exempted limited partnership, Soleus Capital, LLC, a Delaware limited liability company, Soleus Capital Group, LLC, a Delaware limited liability company, and Mr. Guy Levy, an individual, hereby agree to file jointly the statement on Schedule 13G to which this Joint Filing Agreement is attached, and any amendments t |
|
| September 1, 2022 |
IRMD / Iradimed Corp / Soleus Capital Master Fund, L.P. - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* IRADIMED CORPORATION (Name of Issuer) Common Stock (Title of Class of Securities) 46266A109 (CUSIP Number) August 29, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sched |
|
| August 5, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| July 29, 2022 |
IRADIMED CORPORATION CONDENSED BALANCE SHEETS EXHIBIT 99.1 IRADIMED CORPORATION Announces Second Quarter 2022 Financial Results ? Reports second quarter 2022 revenue of $12.7 million, GAAP diluted EPS of $0.26 and non-GAAP diluted EPS of $0.26 ? Announces third quarter 2022 financial guidance Winter Springs, Florida, July 29, 2022 ? IRADIMED CORPORATION (the ?Company?) (NASDAQ: IRMD), announced today its financial results for the three and si |
|
| July 29, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): July 29, 2022 IRADIMED CORPORATION (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-36534 73-1408526 (Commission File Number) (IRS Employer Identification No. |
|
| June 13, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): June 10, 2022 IRADIMED CORPORATION (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-36534 73-1408526 (Commission File Number) (IRS Employer Identification No. |
|
| May 26, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): May 21, 2022 IRADIMED CORPORATION (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-36534 73-1408526 (Commission File Number) (IRS Employer Identification No. |
|
| May 26, 2022 |
IRADIMED Names John F. Glenn Chief Financial Officer EXHIBIT 99.1 IRADIMED Names John F. Glenn Chief Financial Officer Winter Springs, Florida, May 26, 2022 ? iRadimed Corporation (NASDAQ:IRMD), today announced that John (Jack) Glenn has been appointed Chief Financial Officer effective on or before June 20, 2022. Mr. Glenn will assume responsibility for all areas of accounting and finance, including business planning and modeling, organizational res |
|
| May 26, 2022 |
Employment Agreement between the Registrant and John F Glenn, dated May 21, 2022 EXHIBIT 10.1 CONFIDENTIAL EMPLOYMENT AGREEMENT This Employment Agreement (the ?Agreement?) is made on the 21st day of May, 2022 between Iradimed Corporation, a Delaware corporation, having offices at 1025 Willa Springs Drive, Winter Springs, Florida (?Iradimed? or ?Company?), and John (Jack) Glenn (?Executive?). WITNESSETH: WHEREAS, Iradimed desires to employ Executive upon the terms and condition |
|
| May 6, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 29, 2022 |
IRADIMED CORPORATION Announces First Quarter 2022 Financial Results Exhibit 99.1 IRADIMED CORPORATION Announces First Quarter 2022 Financial Results ? Reports first quarter 2022 revenue of $12.3 million, GAAP diluted EPS of $0.20 and non-GAAP diluted EPS of $0.22 ? Announces second quarter 2022 financial guidance ? Increases full-year 2022 financial guidance Winter Springs, Florida, April 29, 2022 ? iRadimed Corporation (the ?Company?) (NASDAQ: IRMD), announced to |
|
| April 29, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): April 28, 2022 IRADIMED CORPORATION (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-36534 73-1408526 (Commission File Number) (IRS Employer Identification No. |
|
| April 29, 2022 |
IRADIMED CORPORATION Executive Transition IRADIMED CORPORATION Executive Transition Winter Springs, Florida, April 28, 2022 ? iRadimed Corporation (the ?Company?) (NASDAQ: IRMD), announced today announced that Chris Scott, Chief Financial and Operating Officer, has resigned from the Company effective May 27, 2022. |
|
| April 29, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 29, 2022 Iradimed Corporation (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-36534 73-1408526 (Commission File Number) (IRS Employer Identification No. |
|
| April 27, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Defin |
|
| March 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| February 7, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 7, 2022 Iradimed Corporation (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-36534 73-1408526 (Commission File Number) (IRS Employer Identification No. |
|
| February 7, 2022 |
IRADIMED Announces Special $1.00 Per Share Cash Dividend Exhibit 99.1 IRADIMED Announces Special $1.00 Per Share Cash Dividend Winter Springs, Florida, February 7, 2022 ? iRadimed Corporation (the ?Company?) (NASDAQ: IRMD), announced that its Board of Directors approved a special cash dividend of $1.00 per share on the Company?s outstanding common stock. This special cash dividend is payable on February 24, 2022 to shareholders of record at the close of |
|
| February 4, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 4, 2022 Iradimed Corporation (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-36534 73-1408526 (Commission File Number) (IRS Employer Identification No. |
|
| February 4, 2022 |
IRADIMED CORPORATION Announces Fourth Quarter 2021 Financial Results Exhibit 99.1 IRADIMED CORPORATION Announces Fourth Quarter 2021 Financial Results ? Reports fourth quarter 2021 revenue of $11.9 million, GAAP diluted EPS of $0.31 and non-GAAP diluted EPS of $0.33 ? Announces full-year and first quarter 2022 financial guidance Winter Springs, Florida, February 4, 2022 ? iRadimed Corporation (the ?Company?) (NASDAQ: IRMD), a leader in the development of innovative |
|
| November 23, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): November 22, 2021 IRADIMED CORPORATION (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-36534 73-1408526 (Commission File Number) (IRS Employer Identification No. |
|
| November 5, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| October 29, 2021 |
IRADIMED CORPORATION Announces Third Quarter 2021 Financial Results Exhibit 99.1 IRADIMED CORPORATION Announces Third Quarter 2021 Financial Results ? Reports third quarter 2021 revenue of $10.9 million, GAAP diluted EPS of $0.20 and non-GAAP diluted EPS of $0.23 ? Increases full-year 2021 financial guidance Winter Springs, Florida, October 29, 2021 ? iRadimed Corporation (the ?Company?) (NASDAQ: IRMD), a leader in the development of innovative magnetic resonance |
|
| October 29, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 29, 2021 Iradimed Corporation (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-36534 73-1408526 (Commission File Number) (IRS Employer Identification No. |
|
| August 6, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| July 30, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 30, 2021 Iradimed Corporation (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-36534 73-1408526 (Commission File Number) (IRS Employer Identification No. |
|
| July 30, 2021 |
IRADIMED CORPORATION Announces Second Quarter 2021 Financial Results Exhibit 99.1 IRADIMED CORPORATION Announces Second Quarter 2021 Financial Results ? Reports second quarter 2021 revenue of $9.8 million, GAAP diluted EPS of $0.12 and non-GAAP diluted EPS of $0.14 ? Issues Q3 and full year 2021 financial guidance Winter Springs, Florida, July 30, 2021 ? iRadimed Corporation (the ?Company?) (NASDAQ: IRMD), a leader in the development of innovative magnetic resonanc |
|
| July 12, 2021 |
EXHIBIT 10.1 AMENDED AND RESTATED EMPLOYMENT AGREEMENT This Amended and Restated Employment Agreement (the "Agreement") is made on the 8th day of July 2021 (the ?Effective Date?) between Iradimed Corporation, a Delaware corporation, having offices at 1025 Willa Springs Drive, Winter Springs, Florida ("Iradimed" or the "Company"), and Chris Scott (the "Executive"). WITNESSETH: WHEREAS, Executive cu |
|
| July 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8?K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): July 8, 2021 IRADIMED CORPORATION (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-36534 73-1408526 (Commission File Number) (IRS Employer Identification No. |
|
| June 17, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 15, 2021 Iradimed Corporation (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-36534 73-1408526 (Commission File Number) (IRS Employer Identification No. |
|
| June 14, 2021 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 11, 2021 IRADIMED CORPORATION (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-36534 73-1408526 (Commission File Number) (IRS Employer Identification No. |
|
| May 7, 2021 |
Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| May 4, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use o |
|
| April 30, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 30, 2021 IRADIMED CORPORATION (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-36534 73-1408526 (Commission File Number) (IRS Employer Identification No. |
|
| April 30, 2021 |
IRADIMED CORPORATION Announces First Quarter 2021 Financial Results Exhibit 99.1 IRADIMED CORPORATION Announces First Quarter 2021 Financial Results · Reports first quarter 2021 revenue of $9.2 million, GAAP diluted EPS of $0.11 and non-GAAP diluted EPS of $0.13 · Reports combined cash and investments of $52.7 million as of March 31, 2021 Winter Springs, Florida, April 30, 2021 – iRadimed Corporation (the “Company”) (NASDAQ: IRMD), a leader in the development of i |
|
| April 28, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confide |
|
| March 5, 2021 |
Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| February 11, 2021 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 11, 2021 IRADIMED CORPORATION (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-36534 73-1408526 (Commission File Number) (IRS Employer Identification No. |
|
| February 4, 2021 |
IRADIMED CORPORATION Announces Fourth Quarter 2020 Financial Results EX-99.1 2 tm215138d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 IRADIMED CORPORATION Announces Fourth Quarter 2020 Financial Results · Reports fourth quarter 2020 revenue of $8.5 million, GAAP diluted EPS of $0.05 and non-GAAP diluted EPS of $0.07 · Reports combined cash and investments of $52.0 million as of December 31, 2020 Winter Springs, Florida, February 4, 2021 – iRadimed Corporation (the “Company |
|
| February 4, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 4, 2021 IRADIMED CORPORATION (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-36534 73-1408526 (Commission File Number) (IRS Employer Identification No. |
|
| November 6, 2020 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ⌧ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2020 OR ◻ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No.: 001-36534 I |
|
| October 30, 2020 |
IRADIMED CORPORATION Announces Third Quarter 2020 Financial Results Exhibit 99.1 IRADIMED CORPORATION Announces Third Quarter 2020 Financial Results · Reports third quarter 2020 revenue of $7.7 million, GAAP diluted EPS of $0.09 and non-GAAP diluted EPS of $0.11 · Reports combined cash and investments of $49.9 million as of September 30, 2020 Winter Springs, Florida, October 30, 2020 – iRadimed Corporation (the “Company”) (NASDAQ: IRMD), a leader in the developmen |
|
| October 30, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 30, 2020 IRADIMED CORPORATION (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-36534 73-1408526 (Commission File Number) (IRS Employer Identification No. |
|
| September 4, 2020 |
As filed with the Securities and Exchange Commission on September 4, 2020 Registration No. |
|
| September 2, 2020 |
IRADIMED CORPORATION 1025 Willa Springs Drive Winter Springs, FL 32708 VIA EDGAR September 2, 2020 United States Securities and Exchange Commission Division of Corporation Finance 100 F Street NE Washington, DC 20549 Attn: Ms. |
|
| August 20, 2020 |
As Filed with the Securities and Exchange Commission on August 20, 2020 Registration No. |
|
| August 6, 2020 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ⌧ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2020 OR ◻ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No.: 001-36534 IRADIM |
|
| August 6, 2020 |
Iradimed Corporation Amended and Restated 2014 Equity Incentive Plan Exhibit 10.1 IRADIMED CORPORATION AMENDED AND RESTATED 2014 EQUITY INCENTIVE PLAN Iradimed Corporation, a Delaware corporation (the “Company”), sets forth herein the terms of its Amended and Restated 2014 Equity Incentive Plan (the “Plan”), as follows: 1. PURPOSE The Plan, which amends and restates the Iradimed Corporation 2014 Equity Incentive Plan, originally effective April 14, 2014, is intende |
|
| July 30, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 30, 2020 Iradimed Corporation (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-36534 73-1408526 (Commission File Number) (IRS Employer Identification No. |
|
| July 30, 2020 |
IRADIMED CORPORATION CONDENSED BALANCE SHEETS Exhibit 99.1 IRADIMED CORPORATION Announces Second Quarter 2020 Financial Results · Reports second quarter 2020 revenue of $6.8 million, GAAP diluted EPS of $(0.17) and non-GAAP diluted EPS of $0.05 · Reports combined cash and investments of $47.8 million as of June 30, 2020 Winter Springs, Florida, July 30, 2020 – iRadimed Corporation (the “Company”) (NASDAQ: IRMD), a leader in the development of |
|
| July 16, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8‑K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): July 15, 2020 IRADIMED CORPORATION (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-36534 (Commission File Number) 73-1408526 (IRS Employer Identification No. |
|
| July 16, 2020 |
Exhibit 10.1 SEPARATION AGREEMENT This Separation Agreement is between Iradimed Corporation (“Iradimed”) and Louis Waldman (“Employee”). As Employee desires to retire, this Agreement sets forth terms of service and compensation for the remaining time of his employment until retirement. Employee agrees to the following points related to services: - Continue to provide services to Iradimed as full-t |
|
| June 18, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8‑K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): June 16, 2020 IRADIMED CORPORATION (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-36534 73-1408526 (Commission File Number) (IRS Employer Identification No. |
|
| June 18, 2020 |
Exhibit 10.1 CONFIDENTIAL SEPARATION AGREEMENT AND GENERAL RELEASE This CONFIDENTIAL SEPARATION AGREEMENT AND GENERAL RELEASE (“Agreement”) is entered as of this May 28, 2020, between Iradimed Corporation (“Iradimed” or “Company”), and Leslie McDonnell, a resident of the State of Florida (“Executive”). Each of the above may be referred to herein as a “Party” and collectively referred to as “Partie |
|
| June 15, 2020 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): June 12, 2020 IRADIMED CORPORATION (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-36534 73-1408526 (Commission File Number) (IRS Employer Identification No. |
|
| June 3, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☑ Filed by a Party other than the Registrant □ Check the appropriate box: ◻ Preliminary Proxy Statement ◻ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ◻ Definitive Proxy Stat |
|
| May 29, 2020 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8‑K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): May 28, 2020 IRADIMED CORPORATION (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-36534 73-1408526 (Commission File Number) (IRS Employer Identification No. |
|
| May 29, 2020 |
IRADIMED CORPORATION Names Roger Susi as President and Chief Executive Officer Exhibit 99.1 IRADIMED CORPORATION Names Roger Susi as President and Chief Executive Officer Winter Springs, Florida, May 29, 2020 – IRADIMED Corporation (NASDAQ: IRMD), announced today that its Board of Directors has appointed Roger Susi to resume his duties as the Company’s President and Chief Executive Officer after the departure of Leslie McDonnell, who separated from the Company effective May |
|
| May 7, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2020 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No.: 001-36534 IRADIMED CORPORATION (E |
|
| April 30, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 30, 2020 Iradimed Corporation (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-36534 73-1408526 (Commission File Number) (IRS Employer Identification No. |
|
| April 30, 2020 |
IRADIMED CORPORATION CONDENSED BALANCE SHEETS Exhibit 99.1 IRADIMED CORPORATION Announces First Quarter 2020 Financial Results · Reports first quarter 2020 revenue of $8.7 million, GAAP diluted EPS of $0.14 and non-GAAP diluted EPS of $0.18 · Reports combined cash and investments of $47.4 million as of March 31, 2020 Winter Springs, Florida, April 30, 2020 – iRadimed Corporation (the “Company”) (NASDAQ: IRMD), a leader in the development of i |
|
| April 29, 2020 |
Definitive Proxy Statement for our 2020 annual meeting of stockholders filed on April 29, 2020 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confide |
|
| April 7, 2020 |
Exhibit 99.1 IRADIMED CORPORATION Withdraws 2020 Financial Guidance Due to Uncertainties from the Effects of COVID-19 · Expects first quarter 2020 revenue of $8.6 million to $8.7 million Winter Springs, Florida, April 7, 2020 – iRadimed Corporation (NASDAQ: IRMD) announced that it expects to report first quarter 2020 revenue of $8.6 million to $8.7 million and is withdrawing its first quarter and |
|
| April 7, 2020 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 7, 2020 Iradimed Corporation (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-36534 73-1408526 (Commission File Number) (IRS Employer Identification No. |
|
| March 6, 2020 |
IRMD / iRadimed Corporation 10-K - Annual Report - FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2019 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NO. 001-36534 IRADIMED CORPORATION (Exact N |
|
| March 6, 2020 |
Description of Registrant’s Securities Exhibit 4.2 Description of Capital Stock of Iradimed Corporation The following is a description of the capital stock of Iradimed Corporation. Our common stock, par value $0.0001 per share, is registered under Section 12 of the Securities Exchange Act of 1934, as amended; while our preferred stock, par value $0.0001 per share, is not so registered. This description does not describe every aspect of |
|
| February 26, 2020 |
Exhibit 99.1 IRADIMED CORPORATION Announces Retirement of Francis Casey and the Appointment of Steven Kachelmeyer as Vice President of Regulatory Affairs and Quality Assurance Winter Springs, Florida, February 26, 2020 – iRadimed Corporation (NASDAQ: IRMD) announced the retirement of Francis Casey, Vice President of Regulatory Affairs and Quality Assurance, effective June 30, 2020 after leading th |
|
| February 26, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 26, 2020 Iradimed Corporation (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-36534 73-1408526 (Commission File Number) (IRS Employer Identification No. |
|
| February 6, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 6, 2020 Iradimed Corporation (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-36534 73-1408526 (Commission File Number) (IRS Employer Identification No. |
|
| February 6, 2020 |
IRADIMED CORPORATION CONDENSED BALANCE SHEETS Exhibit 99.1 IRADIMED CORPORATION Announces Fourth Quarter 2019 Financial Results · Reports fourth quarter 2019 revenue of $10.9 million, GAAP diluted EPS of $0.26 and non-GAAP diluted EPS of $0.30 · Renewed CE Mark for patient vital signs monitor and shipped associated backlog during the fourth quarter 2019 · Announces 2020 full year and first quarter financial guidance Winter Springs, Florida, F |
|
| January 7, 2020 |
Exhibit 99.1 IRADIMED CORPORATION Announces Retirement of Brent Johnson and the Appointment of MaryBeth Smith as Vice President of Worldwide Sales Winter Springs, Florida, January 7, 2020 – iRadimed Corporation (NASDAQ: IRMD) announced the retirement of Brent Johnson, Executive Vice President of Worldwide Sales and Marketing, effective April 10, 2020 after leading the Company’s commercial efforts |
|
| January 7, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 3, 2020 Iradimed Corporation (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-36534 73-1408526 (Commission File Number) (IRS Employer Identification No. |
|
| January 7, 2020 |
EX-10.1 2 tm201238d1ex10-1.htm EXHIBIT 10.1 Exhibit 10.1 CONFIDENTIAL EMPLOYMENT AGREEMENT This Employment Agreement (the “Agreement”) is made on the 3rd day of January, 2020 between Iradimed Corporation, a Delaware corporation, having offices at 1025 Willa Springs Drive, Winter Springs, Florida (“Iradimed” or “Company”), and MaryBeth Smith, an individual residing at 1895 Dove Mountain Ct., Reno, |
|
| December 12, 2019 |
Exhibit 99.1 IRADIMED CORPORATION Completes CE Mark Renewal Process For Its MRI Compatible Patient Vital Signs Monitoring System · Immediately resumes shipments of patient vital signs monitoring systems into all markets requiring CE Mark Winter Springs, Florida, December 12, 2019 – iRadimed Corporation (NASDAQ: IRMD), a leader in the development of innovative magnetic resonance imaging (“MRI”) med |
|
| December 12, 2019 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 12, 2019 Iradimed Corporation (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-36534 73-1408526 (Commission File Number) (IRS Employer Identification No. |
|
| November 7, 2019 |
IRMD / iRadimed Corporation 10-Q - Quarterly Report - 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2019 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No.: 001-36534 I |
|
| November 7, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): November 5, 2019 IRADIMED CORPORATION (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-36534 (Commission File Number) 73-1408526 (IRS Employer Identification No. |
|
| October 30, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): October 30, 2019 IRADIMED CORPORATION (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-36534 73-1408526 (Commission File Number) (IRS Employer Identification No. |
|
| October 30, 2019 |
IRADIMED CORPORATION CONDENSED BALANCE SHEETS Exhibit 99.1 IRADIMED CORPORATION Announces Third Quarter 2019 Financial Results · Reports third quarter 2019 revenue of $10.0 million, GAAP diluted EPS of $0.20 and non-GAAP diluted EPS of $0.23 · Updates full-year financial guidance Winter Springs, Florida, October 30, 2019 — IRADIMED CORPORATION (NASDAQ: IRMD), a leader in the development of innovative magnetic resonance imaging (“MRI”) medical |
|
| October 8, 2019 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): October 8, 2019 IRADIMED CORPORATION (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-36534 73-1408526 (Commission File Number) (IRS Employer Identification No. |
|
| October 8, 2019 |
IRADIMED CORPORATION Resolves Warning Letter Related to Its Infusion Pump System EX-99.1 2 a19-196831ex99d1.htm EX-99.1 Exhibit 99.1 IRADIMED CORPORATION Resolves Warning Letter Related to Its Infusion Pump System Winter Springs, Florida, October 8, 2019 — IRADIMED CORPORATION (NASDAQ: IRMD), today announced that it received a close-out letter from the U.S. Food and Drug Administration resolving all issues cited in the August 2014 warning letter. “The resolution of the warning |
|
| October 8, 2019 |
Exhibit 99.2 October 2, 2019 Roger E. Susi President Iradimed Corporation 1025 Willa Springs Drive Winter Springs, FL 32708-5235 Dear Mr. Susi: The Food and Drug Administration has completed an evaluation of your firm’s corrective actions in response to our Warning Letter FLA-14-21 dated August 18, 2014. Based on our evaluation, it appears that you have addressed the violation(s) contained in this |
|
| August 26, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8‑K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): August 23, 2019 IRADIMED CORPORATION (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-36534 73-1408526 (Commission File Number) (IRS Employer Identification No. |
|
| August 26, 2019 |
EX-10.1 2 exhibit10-1.htm First Amended and Restated SEPARATION AGREEMENT This First Amended and Restated Separation Agreement is between Iradimed Corporation (“Iradimed”) and John McCreery (“Employee”). As Employee desires to retire, this Agreement sets forth terms of service and compensation for the remaining time of his employment until retirement. Employee agrees to the following points relate |
|
| August 7, 2019 |
IRMD / iRadimed Corporation 10-Q - Quarterly Report - 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2019 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No.: 001-36534 IRADIM |
|
| July 30, 2019 |
IRADIMED CORPORATION CONDENSED BALANCE SHEETS Exhibit 99.1 IRADIMED CORPORATION Announces Second Quarter 2019 Financial Results · Reports second quarter 2019 revenue of $9.2 million · Reports second quarter 2019 GAAP diluted EPS of $0.17 and non-GAAP diluted EPS of $0.20 · Updates full year earnings guidance Winter Springs, Florida, July 30, 2019 — IRADIMED CORPORATION (NASDAQ: IRMD), a leader in the development of innovative magnetic resonan |
|
| July 30, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): July 30, 2019 IRADIMED CORPORATION (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-36534 73-1408526 (Commission File Number) (IRS Employer Identification No. |
|
| July 29, 2019 |
EX-10.1 2 exhibit10-1.htm EMPLOYMENT AGREEMENT This Employment Agreement (the “Agreement”) is made on the 24 day of July, 2019 between Iradimed Corporation, a Delaware corporation, having offices at 1025 Willa Springs Drive, Winter Springs, Florida (“Iradimed” or “Company”), and Leslie McDonnell (“Executive”). WITNESSETH: WHEREAS, Iradimed desires to employ Executive upon the terms and conditions |
|
| July 29, 2019 |
Employment Agreement between the Registrant and Roger Susi, dated July 24, 2019 EX-10.2 3 exhibit10-2.htm CONFIDENTIAL EMPLOYMENT AGREEMENT This agreement is made on 24th day of July, 2019 (the “Effective Date”) between Iradimed Corporation, having offices at 1025 Willa Springs Drive, Winter Springs, Florida (“Iradimed” or “Company”), and ROGER SUSI (“Executive”). WITNESSETH: WHEREAS, Iradimed desires to employ Executive upon the terms and conditions hereinafter stated, and; |
|
| July 29, 2019 |
IRADIMED CORPORATION Names Leslie McDonnell as President and Chief Executive Officer EX-99.1 4 exhibit99-1.htm IRADIMED CORPORATION Names Leslie McDonnell as President and Chief Executive Officer Winter Springs, Florida, July 29, 2019 – IRadimed Corporation (NASDAQ: IRMD) announced today that its Board of Directors unanimously appointed Leslie McDonnell, to succeed Roger Susi as President and Chief Executive Officer. Mr. Susi will step down as President and CEO on August 19, 2019 |
|
| July 29, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8‑K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): July 29, 2019 IRADIMED CORPORATION (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-36534 (Commission File Number) 73-1408526 (IRS Employer Identification No. |
|
| June 14, 2019 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): June 14, 2019 IRADIMED CORPORATION (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-36534 73-1408526 (Commission File Number) (IRS Employer Identification No. |
|
| May 17, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): May 17, 2019 IRADIMED CORPORATION (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-36534 73-1408526 (Commission File Number) (IRS Employer Identification No. |
|
| May 8, 2019 |
IRMD / iRadimed Corporation 10-Q Quarterly Report 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2019 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No.: 001-36534 IRADI |
|
| May 8, 2019 |
Exhibit 10.1 Amendment Agreement to Supply Agreement This Amendment Agreement (hereinafter referred to as this “Amendment”) is made and entered into as of February 26th, 2019 between Iradimed Corporation, having its principal place of business at 1025 Willa Springs Drive. Winter Springs, FL 32708 USA (hereinafter referred to as “Iradimed”) and FUKOKU CO., LTD,, having its principal place of busine |
|
| April 30, 2019 |
IRADIMED CORPORATION CONDENSED BALANCE SHEETS Exhibit 99.1 IRADIMED CORPORATION Announces First Quarter 2019 Financial Results · Reports first quarter 2019 revenue of $8.4 million · Reports first quarter 2019 GAAP diluted EPS of $0.15 and non-GAAP diluted EPS of $0.13 Winter Springs, Florida, April 30, 2019 — IRADIMED CORPORATION (NASDAQ:IRMD), a leader in the development of innovative magnetic resonance imaging (“MRI”) medical devices and th |
|
| April 30, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): April 30, 2019 IRADIMED CORPORATION (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-36534 73-1408526 (Commission File Number) (IRS Employer Identification No. |
|
| April 30, 2019 |
IRMD / iRadimed Corporation DEF 14A DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confide |
|
| March 29, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8‑K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): March 26, 2019 IRADIMED CORPORATION (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-36534 73-1408526 (Commission File Number) (IRS Employer Identification No. |
|
| March 7, 2019 |
IRMD / iRadimed Corporation 10-K (Annual Report) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2018 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NO. 001-36534 IRADIMED CO |
|
| February 6, 2019 |
IRADIMED CORPORATION CONDENSED BALANCE SHEETS EX-99.1 2 a19-40501ex99d1.htm EX-99.1 Exhibit 99.1 IRADIMED CORPORATION Announces Fourth Quarter 2018 Financial Results · Reports fourth quarter 2018 revenue of $8.3 million · Reports fourth quarter 2018 GAAP diluted EPS of $0.14 and non-GAAP diluted EPS of $0.16 · Announces 2019 full year and first quarter financial guidance Winter Springs, Florida, February 6, 2019 — IRADIMED CORPORATION (NASDAQ |
|
| February 6, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): February 6, 2019 IRADIMED CORPORATION (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-36534 73-1408526 (Commission File Number) (IRS Employer Identification No. |
|
| January 22, 2019 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): January 22, 2019 IRADIMED CORPORATION (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-36534 73-1408526 (Commission File Number) (IRS Employer Identification No. |
|
| January 22, 2019 |
Exhibit 99.1 IRADIMED CORPORATION Expects Minor Impact to 2019 Revenue After Temporarily Suspending Shipments of MRI Compatible Patient Vital Signs Monitoring Systems in European Markets · Action being taken after CE mark expiration · Expects negative impact to full-year 2019 revenue of approximately two percent Winter Springs, Florida, January 22, 2019 — IRADIMED CORPORATION (NASDAQ: IRMD), a lea |
|
| November 7, 2018 |
IRMD / iRadimed Corporation 10-Q (Quarterly Report) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2018 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No.: 001-36534 I |
|
| October 30, 2018 |
IRADIMED CORPORATION CONDENSED BALANCE SHEETS Exhibit 99.1 IRADIMED CORPORATION Announces Third Quarter 2018 Financial Results · Reports third quarter 2018 revenue of $7.6 million · Reports third quarter 2018 GAAP diluted EPS of $0.20 and non-GAAP diluted EPS of $0.14 · Increases full year 2018 revenue, GAAP and non-GAAP diluted earnings guidance Winter Springs, Florida, October 30, 2018 — IRADIMED CORPORATION (NASDAQ:IRMD), a leader in the d |
|
| October 30, 2018 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): October 30, 2018 IRADIMED CORPORATION (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-36534 73-1408526 (Commission File Number) (IRS Employer Identification No. |
|
| September 24, 2018 |
Employment Agreement Modification between the Registrant and John McCreery, dated September 14, 2018 EMPLOYMENT AGREEMENT MODIFICATION This modification is made on the 14th day of September, 2018 to that certain Employment Agreement dated March 28, 2017 between Iradimed Corporation, a Delaware corporation, having offices at 1025 Will Springs Dr. |
|
| September 24, 2018 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8‑K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): September, 14, 2018 IRADIMED CORPORATION (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-36534 73-1408526 (Commission File Number) (IRS Employer Identification No. |
|
| September 24, 2018 |
Employment Agreement between the Registrant and Francis Casey, dated September 21, 2018 CONFIDENTIAL EMPLOYMENT AGREEMENT This agreement is made on the 21st day of September, 2018, between Iradimed Corporation, a Delaware corporation, having offices at 1025 Willa Springs Drive, Winter Springs, Florida (“Iradimed” or “Company”), and Francis Casey (“Employee”). |
|
| September 24, 2018 |
Employment Agreement between the Registrant and Louis Waldman, dated September 18, 2018 CONFIDENTIAL EMPLOYMENT AGREEMENT This agreement is made on the 18th day of September, 2018, between Iradimed Corporation, a Delaware corporation, having offices at 1025 Willa Springs Drive, Winter Springs, Florida (“Iradimed” or “Company”), and Louis Waldman (“Employee”). |
|
| September 19, 2018 |
Third Amended and Restated Bylaws of the Registrant THIRD AMENDED AND RESTATED BYLAWS OF IRADIMED CORPORATION A Delaware Corporation ARTICLE I: OFFICES SECTION 1. |
|
| September 19, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8‑K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): September 13, 2018 IRADIMED CORPORATION (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-36534 (Commission File Number) 73-1408526 (IRS Employer Identification No. |
|
| August 8, 2018 |
IRMD / iRadimed Corporation 10-Q (Quarterly Report) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2018 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No.: 001-36534 IRADIM |
|
| July 31, 2018 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): July 31, 2018 IRADIMED CORPORATION (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-36534 73-1408526 (Commission File Number) (IRS Employer Identification No. |
|
| July 31, 2018 |
IRADIMED CORPORATION CONDENSED BALANCE SHEETS Exhibit 99.1 IRADIMED CORPORATION Announces Second Quarter 2018 Financial Results · Reports second quarter 2018 revenue of $7.4 million · Reports second quarter 2018 GAAP diluted EPS of $0.11 and non-GAAP diluted EPS of $0.14 · Increases full year 2018 revenue, GAAP and non-GAAP diluted earnings guidance Winter Springs, Florida, July 31, 2018 — IRADIMED CORPORATION (NASDAQ:IRMD), a leader in the d |
|
| June 11, 2018 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): June 8, 2018 IRADIMED CORPORATION (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-36534 73-1408526 (Commission File Number) (IRS Employer Identification No. |
|
| May 8, 2018 |
IRMD / iRadimed Corporation 10-Q (Quarterly Report) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2018 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No.: 001-36534 IRADI |
|
| April 30, 2018 |
IRADIMED CORPORATION CONDENSED BALANCE SHEETS EX-99.1 2 a18-124411ex99d1.htm EX-99.1 Exhibit 99.1 IRADIMED CORPORATION Announces First Quarter 2018 Financial Results · Reports first quarter 2018 revenue of $7.1 million · Reports first quarter 2018 GAAP diluted EPS of $0.07 and non-GAAP diluted EPS of $0.10 · Increases full year 2018 GAAP and non-GAAP diluted EPS guidance Winter Springs, Florida, April 30, 2018 — IRADIMED CORPORATION (NASDAQ:I |
|
| April 30, 2018 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): April 30, 2018 IRADIMED CORPORATION (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-36534 73-1408526 (Commission File Number) (IRS Employer Identification No. |
|
| April 27, 2018 |
IRMD / iRadimed Corporation DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confide |
|
| March 8, 2018 |
IRMD / iRadimed Corporation 10-K (Annual Report) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2017 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NO. 001-36534 IRADIMED CO |
|
| February 6, 2018 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): February 6, 2018 IRADIMED CORPORATION (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-36534 73-1408526 (Commission File Number) (IRS Employer Identification No. |
|
| February 6, 2018 |
IRADIMED CORPORATION CONDENSED BALANCE SHEETS EX-99.1 2 a18-54091ex99d1.htm EX-99.1 Exhibit 99.1 IRADIMED CORPORATION Announces Fourth Quarter 2017 Financial Results · Reports fourth quarter 2017 revenue of $6.7 million · Reports fourth quarter 2017 GAAP diluted EPS of $0.02 and non-GAAP diluted EPS of $0.10 · Records one-time non-cash charge of $0.5 million related to tax reform Winter Springs, Florida, February 6, 2018 — IRADIMED CORPORATIO |
|
| January 22, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): January 22, 2018 IRADIMED CORPORATION (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-36534 73-1408526 (Commission File Number) (IRS Employer Identification No. |
|
| January 22, 2018 |
IRADIMED CORPORATION Announces 2018 Annual and First Quarter Financial Guidance Exhibit 99.1 IRADIMED CORPORATION Announces 2018 Annual and First Quarter Financial Guidance ? Announces Preliminary Full Year and Fourth Quarter 2017 Revenue ? Announces Fourth Quarter 2017 Financial Results Conference Call Date Winter Springs, Florida, January 22, 2018 ? IRADIMED CORPORATION (NASDAQ:IRMD), a leader in the development of innovative magnetic resonance imaging (MRI) medical devices |
|
| November 6, 2017 |
IRMD / iRadimed Corporation 10-Q (Quarterly Report) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2017 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No.: 001-36534 I |
|
| November 3, 2017 |
EX-10.1 2 a17-252111ex10d1.htm EX-10.1 Exhibit 10.1 AMENDMENT TO WARRANT TO PURCHASE COMMON STOCK This Amendment to Warrant to Purchase Common Stock (this “Amendment”), dated as of July 17, 2017, to the Warrant to Purchase Common Stock, made as of July 21, 2014 (the “Warrant”), is entered into by and between Iradimed Corporation, a Delaware corporation (the “Company”) and Lisa Walters-Hoffert, the |
|
| November 3, 2017 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K/A CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): July 21, 2017 IRADIMED CORPORATION (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-36534 73-1408526 (Commission File Number) (IRS Employer Identification No. |
|
| October 30, 2017 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): October 30, 2017 IRADIMED CORPORATION (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-36534 73-1408526 (Commission File Number) (IRS Employer Identification No. |
|
| October 30, 2017 |
IRADIMED CORPORATION CONDENSED BALANCE SHEETS Exhibit 99.1 IRADIMED CORPORATION Announces Third Quarter 2017 Financial Results · Reports third quarter 2017 revenue of $5.7 million · Reports third quarter 2017 GAAP diluted EPS of $0.02 and non-GAAP diluted EPS of $0.07 · Increases full year 2017 non-GAAP diluted EPS guidance Winter Springs, Florida, October 30, 2017 IRADIMED CORPORATION (NASDAQ:IRMD), a leader in the development of innovativ |
|
| October 26, 2017 |
IRADIMED CORPORATION Announces FDA 510(k) Clearance of MRI Compatible Patient Vital Signs Monitor Exhibit 99.1 IRADIMED CORPORATION Announces FDA 510(k) Clearance of MRI Compatible Patient Vital Signs Monitor Winter Springs, Florida, October 26, 2017 IRADIMED CORPORATION (NASDAQ:IRMD), today announced FDA 510(k) clearance of its 3880 Magnetic Resonance Imaging (MRI) compatible patient vital signs monitoring system. We are excited to announce receipt of FDA 510(k) clearance and launch our |
|
| October 26, 2017 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): October 26, 2017 IRADIMED CORPORATION (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-36534 73-1408526 (Commission File Number) (IRS Employer Identification No. |
|
| August 4, 2017 |
IRMD / iRadimed Corporation 10-Q (Quarterly Report) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2017 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No.: 001-36534 IRADIM |
|
| July 28, 2017 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): July 28, 2017 IRADIMED CORPORATION (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-36534 73-1408526 (Commission File Number) (IRS Employer Identification No. |
|
| July 28, 2017 |
IRADIMED CORPORATION CONDENSED BALANCE SHEETS Exhibit 99.1 IRADIMED CORPORATION Announces Second Quarter 2017 Financial Results · Reports second quarter 2017 revenue of $5.5 million · Reports second quarter 2017 GAAP diluted EPS of $0.03 and non-GAAP diluted EPS of $0.06 Winter Springs, Florida, July 28, 2017 IRADIMED CORPORATION (NASDAQ:IRMD), a leader in the development of innovative magnetic resonance imaging (MRI) medical devices and th |
|
| July 21, 2017 |
AMENDMENT TO WARRANT TO PURCHASE COMMON STOCK This Amendment to Warrant to Purchase Common Stock (this ? Amendment?), dated as of July 17, 2017, to the Warrant to Purchase Common Stock, made as of July 21, 2014 (the ? Warrant? ), is entered into by and between Iradimed Corporation, a Delaware corporation (the ? Company?) and Roth Capital Partners, LLC, the registered holder of the Warrant (the ?Holder?). |
|
| July 21, 2017 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8‑K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): July 17, 2017 IRADIMED CORPORATION (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-36534 (Commission File Number) 73-1408526 (IRS Employer Identification No. |
|
| July 21, 2017 |
EX-10.1 3 ex10-2.htm AMENDMENT TO WARRANT TO PURCHASE COMMON STOCK This Amendment to Warrant to Purchase Common Stock (this “Amendment”), dated as of July 17, 2017, to the Warrant to Purchase Common Stock, made as of July 21, 2014 (the “Warrant”), is entered into by and between Iradimed Corporation, a Delaware corporation (the “Company”’) and Monarch Capital Group, LLC, the registered holder of th |
|
| July 21, 2017 |
AMENDMENT TO WARRANT TO PURCHASE COMMON STOCK AMENDMENT TO WARRANT TO PURCHASE COMMON STOCK This Amendment to Warrant to Purchase Common Stock (this ? Amendment??), dated as of July 17, 2017, to the Warrant to Purchase Common Stock, made as of July 21,2014 (the ? Warrant??), is entered into by and between Iradimed Corporation, a Delaware corporation (the ? Company?) and Roth Capital Partners, LLC, the registered holder of the Warrant (the ?? Holder??). |
|
| June 12, 2017 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): June 9, 2017 IRADIMED CORPORATION (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-36534 73-1408526 (Commission File Number) (IRS Employer Identification No. |
|
| May 5, 2017 |
iRadimed 10-Q (Quarterly Report) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2017 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No.: 001-36534 IRADI |
|
| April 28, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confide |
|
| April 28, 2017 |
IRADIMED CORPORATION CONDENSED BALANCE SHEETS Exhibit 99.1 IRADIMED CORPORATION Announces First Quarter 2017 Financial Results · Reports first quarter 2017 revenue of $5.2 million · Reports first quarter 2017 GAAP diluted EPS of $(0.02) and non-GAAP diluted EPS of $0.00 · Announces $8 million share repurchase program Winter Springs, Florida, April 28, 2017 IRADIMED CORPORATION (NASDAQ:IRMD), the only known provider of non-magnetic intraveno |
|
| April 28, 2017 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): April 28, 2017 IRADIMED CORPORATION (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-36534 73-1408526 (Commission File Number) (IRS Employer Identification No. |
|
| March 30, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): March 30, 2017 IRADIMED CORPORATION (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-36534 73-1408526 (Commission File Number) (IRS Employer Identification No. |
|
| March 30, 2017 |
Exhibit 10.1 CONFIDENTIAL EMPLOYMENT AGREEMENT This agreement is made on the 28th day of March, 2017 between Iradimed Corporation, a Delaware corporation, having offices at 1025 Willa Springs Dr., Winter Springs, Florida (?Iradimed? or ?Company?), and John K. McCreery (?Executive?). WITNESSETH: WHEREAS, Iradimed desires to employ Executive upon the terms and conditions hereinafter stated, and; WHE |
|
| March 30, 2017 |
IRADIMED Names John McCreery Chief Operating Officer Exhibit 99.1 IRADIMED Names John McCreery Chief Operating Officer Winter Springs, Florida, March 30, 2017 IRADIMED CORPORATION (NASDAQ:IRMD), today announced that John McCreery has been appointed Chief Operating Officer, a new position within the Company. Mr. McCreery will have primary responsibility over the regulatory, manufacturing and engineering departments of the Company. Mr. McCreery, 62, |
|
| March 10, 2017 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the Fiscal Year Ended December 31, 2016 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2016 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM |
|
| February 6, 2017 |
IRADIMED CORPORATION CONDENSED BALANCE SHEETS EX-99.1 2 a17-38041ex99d1.htm EX-99.1 Exhibit 99.1 IRADIMED CORPORATION Announces Fourth Quarter 2016 Financial Results · Reports fourth quarter 2016 revenue of $6.0 million · Reports fourth quarter 2016 GAAP diluted EPS of $0.10 and non-GAAP diluted EPS of $0.11 Winter Springs, Florida, February 6, 2017 — IRADIMED CORPORATION (NASDAQ:IRMD), the only known provider of non-magnetic intravenous (IV) |
